Helius Medical Soars 6.11% on CignaHealth Authorization

On June 20, 2025, Helius Medical's stock price surged by 6.11% in pre-market trading, marking a significant rise in investor confidence.

Helius Medical Technologies, Inc. has recently achieved a major breakthrough in expanding the adoption of its PoNS Device. CignaHealth has become the fifth major payer to authorize claims for payment for the PoNS Device, following the recent authorization by Anthem MultiPlan. This development is a critical step towards wider adoption of the technology, as it boosts patient access and potential revenue.

This authorization is likely to have a positive impact on Helius Medical's share price, as it enhances the device's market reach and financial viability. The company's strides in gaining insurance reimbursement for the PoNS Device are expected to drive further growth and adoption in the healthcare sector.